(Bimekizumab)Biosimilar Reference Antibody-GS40088主打

货号：GS40088

Bimekizumab is a humanized monoclonal antibody (IgG1) designed as a dual inhibitor of interleukin-17 (IL-17). It uniquely and simultaneously neutralizes two key pro-inflammatory cytokines: IL-17A and IL-17F. These cytokines are pivotal drivers of the inflammatory response in psoriatic diseases. By binding to and inhibiting both, bimekizumab provides a broader suppression of the IL-17 pathway than agents targeting only IL-17A. It is approved for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, and active axial spondyloarthritis (including ankylosing spondylitis). Clinical trials have demonstrated rapid, deep, and sustained clearance of skin and joint symptoms.